Analyst Expectations for Autolus Therapeutics’s Future
Within the last quarter, Autolus Therapeutics (NASDAQ:AUTL) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Autolus Therapeutics Presented Clinical Data Updates Saturday At 2023 ASH Meeting
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two oral presentations and two poster presentations at the
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 62.0% to $1.62 during Tuesday’s regular session. The market value…
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 56.0% to $0.81 during Wednesday’s after-market session. Today’s trading volume…
Autolus Therapeutics To Present Clinical Data Updates At The American Society Of Hematology Annual Meeting 2023 In Two Oral Presentations And Two Poster Presentations
obe-cel: oral presentation – pooled analysis of the ongoing FELIX Phase Ib/II studyAUTO8: oral presentation of MCARTY Phase I Studyobe-cel: poster presentation - pooled analysis from ALLCAR19 and FELIX Phase Ib studies
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell
• AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Autolus Therapeutics’ Obe-Cel’s Shows Compelling Safety Over Gilead’s Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Autolus Therapeutics Announces Publication In Cancer Immunology Research
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Cancer Immunology
Where Autolus Therapeutics Stands With Analysts
Analysts have provided the following ratings for Autolus Therapeutics (NASDAQ:AUTL) within the last quarter: Bullish Somewhat Bullish Indifferent…